Articles dans des revues avec comité de lecture (161)
121.
Toillon, R. A., Magné, N., Laïos, I., Lacroix, M., Duvillier, H., Lagneaux, L., Devriendt, D., Van Houtte, P., & Leclercq, G. (2005). Interaction between estrogen receptor alpha, ionizing radiation and (anti-) estrogens in breast cancer cells. Breast cancer research and treatment, 93(3), 207-215. doi:10.1007/s10549-005-5148-0122.
Tondreau, T., Meuleman, N., Delforge, A., Dejeneffe, M., Leroy, R., Massy, M., Mortier, C., Bron, D., & Lagneaux, L. (2005). Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem cells, 23(8), 1105-1112. doi:10.1634/stemcells.2004-0330123.
Achachi, A., Florins, A., Gillet, N., Debacq, C., Urbain, P., Foutsop, G. M., Vandermeers, F., Jasik, A., Reichert, M., Kerkhofs, P., Lagneaux, L., Burny, A., Kettmann, R., & Willems, L. (2005). Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proceedings of the National Academy of Sciences of the United States of America, 102(29), 10309-10314. doi:10.1073/pnas.0504248102124.
Tondreau, T., Lagneaux, L., Dejeneffe, M., Massy, M., Mortier, C., Delforge, A., & Bron, D. (2004). Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation, 72(7), 319-326. doi:10.1111/j.1432-0436.2004.07207003.x125.
Dumon, J. C., Journé, F., Kheddoumi, N., Lagneaux, L., & Body, J.-J. (2004). Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. European urology, 45(4), 521-8; discussion 528-9. doi:10.1016/j.eururo.2003.12.012126.
Tondreau, T., Lagneaux, L., Dejeneffe, M., Delforge, A., Massy, M., Mortier, C., & Bron, D. (2004). Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy, 6(4), 372-379. doi:10.1080/14653240410004943127.
Lewalle, P., Delforge, A., Aoun, M., Crombez, P., De Wilde, V., Theunissen, K., Lagneaux, L., Nowak, B., Misplon, V., Bron, D., & Martiat, P. (2004). Growth factors and DLI in adult haploidentical transplant: a three-step pilot study towards patient and disease status adjusted management. Blood cells, molecules, & diseases, 33(3), 256-260. doi:10.1016/j.bcmd.2004.08.012128.
Lagneaux, L., de Meulenaer, E. C., Delforge, A., Dejeneffe, M., Massy, M., Moerman, C., Hannecart, B., Canivet, Y., Lepeltier, M. F., & Bron, D. (2003). Ultrasonic low-energy treatment: a novel approach to induce apoptosis in human leukemic cells. Experimental hematology, 30(11), 1293-1301. doi:10.1016/S0301-472X(02)00920-7129.
Snoeck, R., Andrei, G., Bodaghi, B., Lagneaux, L., Daelemans, D., de Clercq, E., Neyts, J., Schols, D., Naesens, L., Michelson, S., Bron, D., Otto, M. J., Bousseau, A., Nemecek, C., & Roy, C. (2002). 2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral research, 55(3), 413-424. doi:10.1016/S0166-3542(02)00074-8130.
Bron, D., De Bruyn, C., Lagneaux, L., Tondreau, T., & Delforge, A. (2002). Les cellules souches hématopoiétiques: sources, indications et perspectives. Bulletin et mémoires de l'Académie royale de médecine de Belgique, 157(1-2), 135-45; discussion 145-6.131.
Lagneaux, L., Delforge, A., Dejeneffe, M., Massy, M., Bernier, M., & Bron, D. (2002). Hydroxychloriquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio. Leukemia & lymphoma, 43(5), 1087-1095.132.
Lagneaux, L., Delforge, A., Carlier, S., Massy, M., Bernier, M., & Bron, D. (2001). Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. British journal of haematology, 112(2), 344-352. doi:10.1046/j.1365-2141.2001.02553.x